Anna J Moore

US Patent:

8563043, Oct 22, 2013

Filed:

Mar 16, 2010

Appl. No.:

13/142730

Inventors:

Zdravka Medarova - Methuen MA, US
Anna Moore - Dracut MA, US
Mehmet Yigit - Malden MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 9/14

US Classification:

424489, 424490

Abstract:

A gold-coated iron oxide nanoparticle, method of making thereof, and method of using thereof is disclosed. The nanoparticle is substantially toxin free (making it clinically applicable), easily functionalized, and can serve as a contrast agent for a number of imaging techniques, including imaging a subject in at least two distinct imaging modes. Further, the nanoparticle is well-suited for therapeutic uses.

US Patent:

20090155292, Jun 18, 2009

Filed:

Mar 7, 2008

Appl. No.:

12/044435

Inventors:

Pedro SANTAMARIA - Calgary, CA
Anna MOORE - Dracut MA, US

International Classification:

A61K 39/39
C12Q 1/68
G01N 33/566
A61P 3/10

US Classification:

4241851, 435 6, 436501

Abstract:

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.

US Patent:

20110059121, Mar 10, 2011

Filed:

Jul 30, 2010

Appl. No.:

12/848055

Inventors:

Pedro Santamaria - Calgary, CA
Anna Moore - Dracut MA, US

International Classification:

A61K 39/385
C07K 17/00

US Classification:

4241941, 530403

Abstract:

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.

US Patent:

20130129579, May 23, 2013

Filed:

Jun 23, 2011

Appl. No.:

13/806197

Inventors:

Anna Moore - Dracut MA, US
Zdravka Medarova - Methuen MA, US
Subrata Ghosh - Braintree MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

G01N 21/78

US Classification:

422426, 422 69, 422425

Abstract:

A method and device for detecting an analyte in a solution or compound mixture use colorimetric detection to detect the quantity of an analyte in the solution or compound. The analyte sensor demonstrates a clear change in peak light absorption wavelength as a function of the stoichiometric relationship between the analyte sensor and the analyte. The method involves combining the analyte sensor and the analyte in solution and observing a color change of the mixture. Additionally, predefined amounts of the analyte sensor can be added until color change is detected and the quantity of analyte can be determined as a function of the total amount of analyte sensor in the mixture. Alternatively, a device having multiple wells or compartments, each with a different concentration of the analyte sensor. The analyte sample can be introduced to each well and the well that demonstrates the color change can, from its know analyte sensor concentration, be used to quickly and accurately determine the concentration of the analyte.

US Patent:

20140241996, Aug 28, 2014

Filed:

Jul 19, 2012

Appl. No.:

14/233215

Inventors:

Zdravka Medarova - Methuen MA, US
Mehmet V. Yigit - Malden MA, US
Anna Moore - Dracut MA, US

Assignee:

THE GENERAL HOSPITAL CORPORATION - Boston MA

International Classification:

A61K 9/51
A61K 9/50
A61K 49/18
A61K 31/713

US Classification:

424 9322, 424493, 514 44 A

Abstract:

Provided herein are therapeutic nanoparticles having a diameter of between 10 nm to 30 nm, and containing a polymer coating, and a nucleic acid containing a sequence complementary to a sequence within a micro-RNA identified as having a role in cancer cell metastasis or anti-apoptotic activity in a cancer cell (e.g., miR-10b) or a sequence within an mRNA encoding a pro-apoptotic protein that is covalently linked to the nanoparticle. Also provided are pharmaceutical compositions containing these therapeutic nanoparticles. Also provided herein are methods of decreasing cancer cell invasion or metastasis in a subject having a cancer and methods of treating a metastatic cancer in a lymph node in a subject that require the administration of these therapeutic nanoparticles to a subject.